Antiretroviral drugs toxicity and immune status of HIV patients under comprehensive care in Embu, Kenya

Ng'ang'a, Zipporah W.; Gicheru, Michael M.; Namu, Samuel J.

dc.contributor.author	Ng'ang'a, Zipporah W.
dc.contributor.author	Gicheru, Michael M.
dc.contributor.author	Namu, Samuel J.
dc.date.accessioned	2014-12-01T08:54:41Z
dc.date.available	2014-12-01T08:54:41Z
dc.date.issued	2013
dc.identifier.citation	European International Journal of Science and Technology Vol. 2 No. 1 February 2013	en_US
dc.identifier.uri	www.cekinfo.org.uk/images/frontImages/gallery/Vol._2_No..._/7.pdf
dc.identifier.uri	http://hdl.handle.net/123456789/263
dc.description.abstract	The objective of this study was to determine toxicity and immune status of HIV patients under ARVs (Zidovudine, Stavudine and Nevirapine) which comprises first line ARV combination regime currently being used in Kenya. A total of sixty (60) HIV patients participated in the study after consenting to undergo comprehensive care. A control group of forty (40) HIV patients on only contrimoxale (septrin), Analysis of Variance (ANOVA), t-test and correlation coeficient were used to analyse the data. The results showed treatment with ARVs may cause . Based on the findings of this study it is recommended that the ARV drug combination used may be initiated for patients at baseline CD4 counts of 101-150 cells/µl of blood. However change to another ARV drug combination regime may be introduced after three months of use to minimize toxicity associated with prolonged use.	en_US
dc.language.iso	en	en_US
dc.subject	Antiretrovirals	en_US
dc.subject	Toxicity	en_US
dc.subject	Immune status	en_US
dc.subject	Creatinine	en_US
dc.title	Antiretroviral drugs toxicity and immune status of HIV patients under comprehensive care in Embu, Kenya	en_US
dc.type	Article	en_US